Leptin Downregulates Angulin-1 in Active Crohn's Disease via STAT3.
Adult
Biopsy
Caco-2 Cells
Case-Control Studies
Crohn Disease
/ metabolism
Cyclic S-Oxides
/ pharmacology
Down-Regulation
Female
Humans
Intestinal Mucosa
/ metabolism
Leptin
/ metabolism
MARVEL Domain Containing 2 Protein
/ metabolism
Male
Middle Aged
Pyridines
/ pharmacology
Receptors, Lipoprotein
/ metabolism
STAT3 Transcription Factor
/ antagonists & inhibitors
Transcription Factors
/ metabolism
Tyrphostins
/ pharmacology
Young Adult
Crohn’s disease
angulin-1
leptin
tight junction
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
22 Oct 2020
22 Oct 2020
Historique:
received:
02
10
2020
revised:
19
10
2020
accepted:
20
10
2020
entrez:
27
10
2020
pubmed:
28
10
2020
medline:
22
4
2021
Statut:
epublish
Résumé
Crohn's disease (CD) has an altered intestinal barrier function, yet the underlying mechanisms remain to be disclosed. The tricellular tight junction protein tricellulin is involved in the maintenance of the paracellular macromolecule barrier and features an unchanged expression level in CD but a shifted localization. As angulins are known to regulate the localization of tricellulin, we hypothesized the involvement of angulins in CD. Using human biopsies, we found angulin-1 was downregulated in active CD compared with both controls and CD in remission. In T84 and Caco-2 monolayers, leptin, a cytokine secreted by fat tissue and affected in CD, decreased angulin-1 expression. This effect was completely blocked by STAT3 inhibitors, Stattic and WP1066, but only partially by JAK2 inhibitor AG490. The effect of leptin was also seen at a functional level as we observed in Caco-2 cells an increased permeability for FITC-dextran 4 kDa indicating an impaired barrier against macromolecule uptake. In conclusion, we were able to show that in active CD angulin-1 expression is downregulated, which leads to increased macromolecule permeability and is inducible by leptin via STAT3. This suggests that angulin-1 and leptin secretion are potential targets for intervention in CD to restore the impaired intestinal barrier.
Identifiants
pubmed: 33105684
pii: ijms21217824
doi: 10.3390/ijms21217824
pmc: PMC7672602
pii:
doi:
Substances chimiques
Cyclic S-Oxides
0
LSR protein, human
0
Leptin
0
MARVEL Domain Containing 2 Protein
0
MARVELD2 protein, human
0
Pyridines
0
Receptors, Lipoprotein
0
STAT3 Transcription Factor
0
STAT3 protein, human
0
Transcription Factors
0
Tyrphostins
0
WP1066
0
alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide
0
stattic
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : GRK 2318
Références
Protoplasma. 1969;67(2):165-84
pubmed: 5346995
Oncotarget. 2018 Aug 31;9(68):32917-32928
pubmed: 30250639
Clin Cancer Res. 2007 Nov 1;13(21):6351-8
pubmed: 17975147
Am J Physiol. 1991 Oct;261(4 Pt 1):C574-82
pubmed: 1656765
Sci Rep. 2017 Jan 10;7:37049
pubmed: 28071680
Oncol Lett. 2017 Dec;14(6):6776-6782
pubmed: 29151917
Br J Nutr. 2004 Sep;92(3):347-55
pubmed: 15469638
J Biol Chem. 2015 May 29;290(22):14031-44
pubmed: 25882847
J Biol Chem. 1997 Mar 7;272(10):6093-6
pubmed: 9102398
J Immunol. 2013 Apr 1;190(7):3054-8
pubmed: 23447682
J Pathol. 2018 Oct;246(2):217-230
pubmed: 29984492
Biochemistry. 1994 Feb 8;33(5):1172-80
pubmed: 7509190
J Cell Biol. 1965 Jul;26(1):263-91
pubmed: 5859021
Gastrointest Endosc. 2004 Oct;60(4):505-12
pubmed: 15472670
J Crohns Colitis. 2017 Jan;11(1):3-25
pubmed: 27660341
J Cell Sci. 1973 Nov;13(3):763-86
pubmed: 4203962
Oncotarget. 2016 May 10;7(19):27735-52
pubmed: 27036040
Ann N Y Acad Sci. 2017 Jun;1397(1):219-230
pubmed: 28605032
FASEB J. 2004 Apr;18(6):696-8
pubmed: 14977884
Am J Med. 1952 Nov;13(5):583-90
pubmed: 12996536
Annu Rev Physiol. 2008;70:537-56
pubmed: 17937601
PLoS One. 2014 Mar 17;9(3):e91747
pubmed: 24637461
FASEB J. 2010 Nov;24(11):4218-28
pubmed: 20647547
PLoS One. 2019 Jun 24;14(6):e0218812
pubmed: 31233547
J Cell Sci. 2013 Feb 15;126(Pt 4):966-77
pubmed: 23239027
Inflamm Bowel Dis. 2006 Jun;12(6):471-7
pubmed: 16775490
Cancer Res. 2018 Jan 15;78(2):516-527
pubmed: 29187404
J Immunol. 2005 Jun 15;174(12):8090-6
pubmed: 15944317
Gastroenterology. 2017 Feb;152(2):313-321.e2
pubmed: 27793607
J Cell Sci. 2011 Feb 15;124(Pt 4):548-55
pubmed: 21245199
Neurobiol Aging. 2018 Sep;69:292.e1-292.e5
pubmed: 29858039
Gastroenterol Clin Biol. 2003 Nov;27(11):987-91
pubmed: 14732844
J Cell Biol. 2005 Dec 19;171(6):939-45
pubmed: 16365161
Clin Genet. 2018 Apr;93(4):846-852
pubmed: 29178324
Semin Cell Dev Biol. 2014 Dec;36:166-76
pubmed: 25220018
J Biol Chem. 2000 Sep 22;275(38):29338-47
pubmed: 10882725
Clin Exp Immunol. 2008 Mar;151(3):505-18
pubmed: 18234059
Cell Metab. 2007 Dec;6(6):431-45
pubmed: 18054313
J Biol Chem. 2000 Dec 22;275(51):40649-57
pubmed: 11018044
Physiol Genomics. 2016 Dec 1;48(12):928-935
pubmed: 27789735
Mol Cancer Res. 2017 Feb;15(2):165-178
pubmed: 27856957
Gut. 2007 Jan;56(1):61-72
pubmed: 16822808
J Biol Chem. 2000 May 12;275(19):14563-72
pubmed: 10799542
FEBS J. 2005 Jan;272(1):109-19
pubmed: 15634336
Cell Mol Gastroenterol Hepatol. 2017 Mar 23;4(1):33-46
pubmed: 28560287
Front Immunol. 2018 Oct 12;9:1974
pubmed: 30369924
Lancet. 2018 Dec 23;390(10114):2769-2778
pubmed: 29050646
Toxins (Basel). 2018 Oct 08;10(10):
pubmed: 30297616
Best Pract Res Clin Endocrinol Metab. 2015 Oct;29(5):661-70
pubmed: 26522452
Mol Biol Cell. 2009 Aug;20(16):3713-24
pubmed: 19535456
Physiologist. 1977 Feb;20(1):10-8
pubmed: 16304
Nature. 1998 Aug 27;394(6696):897-901
pubmed: 9732873
Mucosal Immunol. 2018 Mar;11(2):345-356
pubmed: 28612843